^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    DLL3 inhibitor

    Related drugs:
    1d
    START-lung: A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2 (clinicaltrials.gov)
    P2, N=48, Recruiting, ETOP IBCSG Partners Foundation | Not yet recruiting --> Recruiting | N=30 --> 48
    Enrollment open • Enrollment change • Trial initiation date
    |
    Imdelltra (tarlatamab-dlle)
    1d
    First Documented Response to Tarlatamab in a Patient With Transformed SCLC Without Actionable Gene Alteration: Case Report. (PubMed, JTO Clin Res Rep)
    She was treated with tarlatamab, achieving 4 months of treatment response with symptomatic relief and improved performance status. This case represents the first documented evidence of the clinical benefit of tarlatamab in transformed SCLC and highlights its therapeutic potential in this challenging setting.
    Journal
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    Imdelltra (tarlatamab-dlle)
    2d
    DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy (clinicaltrials.gov)
    P3, N=670, Recruiting, Boehringer Ingelheim | Not yet recruiting --> Recruiting
    Enrollment open
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    VENTANA DLL3 (SP347) Assay
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • obrixtamig (BI 764532)
    5d
    Transcription Factor Subtype Governs Response and Resistance to DLL3-Directed T-Cell Engagement in Small Cell Lung Cancer. (PubMed, bioRxiv)
    The recent approval of the DLL3×CD3 bispecific T-cell engager tarlatamab represents one of the first meaningful advances in relapsed small cell lung cancer (SCLC) in decades, yet responses remain heterogeneous and resistance is inevitable...These findings underscore the clinical relevance of TF-defined molecular subtypes in human SCLC. More broadly, they highlight the power of integrating longitudinal in vivo plasma transcriptional profiling from patient plasma with functional mouse modeling to uncover clinical and biological mechanisms of response and resistance to cell-surface-targeted therapies.
    Journal
    |
    DLL3 (Delta Like Canonical Notch Ligand 3) • POU2F3 (POU Class 2 Homeobox 3) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1) • NEUROD1 (Neuronal Differentiation 1)
    |
    Imdelltra (tarlatamab-dlle)
    7d
    START-lung: A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2 (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, ETOP IBCSG Partners Foundation
    New P2 trial
    |
    Imdelltra (tarlatamab-dlle)
    7d
    A single arm phase II study evaluating intracranial efficacy of tarlatamab in patients with asymptomatic active brain metastases from small cell lung cancer (2025-522162-75-00)
    P1/2, N=35, Not yet recruiting, Academisch Ziekenhuis Maastricht
    New P1/2 trial
    |
    Imdelltra (tarlatamab-dlle)
    7d
    DeLLphi-313: Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
    P1, N=160, Not yet recruiting, Amgen
    New P1 trial
    |
    Imfinzi (durvalumab) • Imdelltra (tarlatamab-dlle)
    8d
    DAREON-8: DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=46, Active, not recruiting, Boehringer Ingelheim | Trial completion date: Sep 2026 --> Apr 2027
    Trial completion date
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • obrixtamig (BI 764532)
    11d
    Landscape of T-Cell Engagers in Solid Tumors. (PubMed, Oncologist)
    Recent advances seen with tebentafusp in metastatic uveal melanoma and tarlatamab in small-cell lung cancer have validated the approach and driven a rapidly expanding pipeline targeting other tumor associated antigens such as STEAP1, MUC16, and PRAME among others. Collectively, next-generation TCEs guided by rational target selection, context-dependent activation, and biomarker-driven patient stratification, are poised to broaden the reach of immunotherapy in solid tumors. In this review, we synthesize the recent advances that aim to expand the therapeutic window of TCEs for the treatment of solid tumors.
    Journal • IO biomarker
    |
    STEAP1 (STEAP Family Member 1) • PRAME (Preferentially Expressed Antigen In Melanoma)
    |
    Kimmtrak (tebentafusp-tebn) • Imdelltra (tarlatamab-dlle)
    14d
    Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors (clinicaltrials.gov)
    P1/2, N=138, Recruiting, Molecular Partners AG | Initiation date: Jan 2026 --> Apr 2026
    Trial initiation date
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    14d
    ETOP29-25 START-lung: A clinical study to investigate the efficacy of tarlatamab in people with extensive-stage small cell lung cancer (ES-SCLC) whose cancer has progressed during or after prior treatment and who have a limited health status. (2025-522288-13-00)
    P1/2, N=10, Not yet recruiting, ETOP IBCSG Partners Foundation
    New P1/2 trial
    |
    Imdelltra (tarlatamab-dlle)